Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet

Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

(2020) Lin Zhu et al.   Cardiovascular Diabetology

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

(2019) Satoshi Ida et al.   Cardiovascular Diabetology

Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet

(2019) Tomonari Kimura et al.   International Heart Journal

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

(2019) Jean-Charles Fruchart et al.   Cardiovascular Diabetology

Improvement of endothelial dysfunction is mediated through reduction of remnant lipoprotein after statin therapy in patients with coronary artery disease

(2019) Takamitsu Nakamura et al.   Journal of Cardiology

Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up

(2019) Han Saem Jeong et al.   Cardiovascular Diabetology

Improvement of endothelial function by pitavastatin: a meta-analysis

(2018) Niki Katsiki et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia

(2018) Shizuya Yamashita et al.   Journal of Clinical Lipidology

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

(2018) Shun Ishibashi et al.   Journal of Clinical Lipidology

Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells

(2018) Tao Dong et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice

(2018) Masaya Araki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice

(2018) Masami Sairyo et al.   Journal of Atherosclerosis and Thrombosis

Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea

(2018) Jinkwon Kim et al.   Cardiovascular Diabetology

Sex Differences in Renal Inflammation and Injury in High-Fat Diet–Fed Dahl Salt-Sensitive Rats

(2018) Roxanne Fernandes et al.   HYPERTENSION

Physiological Diagnostic Criteria for Vascular Failure

(2018) Atsushi Tanaka et al.   HYPERTENSION

Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice

(2017) Kenta Takei et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice

(2017) Kazufumi Nakamura et al.   PLoS One

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

(2016) Nathalie Hennuyer et al.   ATHEROSCLEROSIS

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

(2016) Shun Ishibashi et al.   ATHEROSCLEROSIS

Postprandial hyperlipidemia as a potential residual risk factor

(2016) Kazufumi Nakamura et al.   Journal of Cardiology

Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals – a randomized cross-over trial

(2014) Toru Miyoshi et al.   BIOMEDICINE & PHARMACOTHERAPY

Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study

(2014) Yuko Ohno et al.   Cardiovascular Diabetology

Triglycerides and cardiovascular disease

(2014) Børge G Nordestgaard et al.   LANCET

Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension

(2013) Kimberly Gilbert et al.   JOURNAL OF HYPERTENSION

Impact of Hypertriglyceridemia on Endothelial Dysfunction During Statin ± Ezetimibe Therapy in Patients With Coronary Heart Disease

(2011) Kei Yunoki et al.   AMERICAN JOURNAL OF CARDIOLOGY

Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction

(2011) Kei Yunoki et al.   ATHEROSCLEROSIS

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

(2011) Uchechukwu K. Sampson et al.   Current Atherosclerosis Reports

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of High Fat Loading in Dahl Salt-Sensitive Rats

(2009) Ai Nagae et al.   CLINICAL AND EXPERIMENTAL HYPERTENSION